Posted by Michael Wonder on 20 Apr 2022
FDA granted CMG901 fast track designation for unresectable or metastatic gastric and gastro-oesophageal junction cancer which have relapsed and/or are refractory to approved therapies
19 April 2022 - Keymed Biosciences announced that the U.S. FDA granted CMG901 fast track designation as monotherapy for the treatment of unresectable or metastatic gastric and gastro-oesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
This designation was granted based on the Phase 1 studies that assessed the safety, tolerability, pharmacokinetic and preliminary efficacy of CMG901.
